16 completed, 5 terminated, 4 recruiting, 4 unknown. 20 Phase 2, 11 Phase 1, 2 Not applicable, 2 Phase 3.
Follow Mantle-cell Lymphoma: new trials by email Literature Review of Mantle-cell Lymphoma trials Research Report on Mantle-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain Acalabrutinib + R-CHOP standard of care, Acalabrutinib combination with Rituximab, Acalabrutinib monotherapy - Mantle-cell Lymphoma | Phase 2 | Recruiting | AstraZeneca | 55 | 2025-09-05 | 2026-10-02 |
| A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies Surovatamig, Prednisone (or equivalent), Rituximab - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 408 | 2025-01-30 | 2026-09-08 |
| Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma Polatuzumab, bendamustin und rituximab - Mantle-cell Lymphoma | Phase 2 | Recruiting | Medical University of Vienna | 16 | 2024-01-02 | 2024-05-29 |
| "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. Mantle-cell Lymphoma, B Cell Chronic Lymphocytic Leukemia | Unknown | University of Milano Bicocca | 30 | 2022-09-08 | 2023-06-05 | |
| A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Ixazomib, Ibrutinib - Mantle-Cell Lymphoma | Phase 1 / Phase 2 | Completed | PrECOG, LLC. | 43 | 2018-08-13 | 2026-06-25 |
| Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors Tazemetostat and [14C] Tazemetostat - Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma | Phase 1 | Completed | Epizyme, Inc. | 3 | 2018-06-20 | 2024-03-22 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders HSCT with TBI Regimen, HSCT with Non-TBI Regimen - Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 300 | 2018-03-30 | 2026-06-25 |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells - Multiple Myeloma, Non-Hodgkin Lymphoma | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 39 | 2017-10-18 | 2022-11-04 |
| Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax - Mantle-Cell Lymphoma | Phase 3 | Completed | Pharmacyclics LLC. | 366 | 2017-06-19 | 2025-07-22 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Fludarabine, Cyclophosphamide, MMF - Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 15 | 2017-05-15 | 2025-07-04 |
| Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers SNS-062 - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Terminated | Sunesis Pharmaceuticals | 39 | 2017-04-28 | 2020-10-19 |
| Allo HSCT Using RIC for Hematological Diseases Allopurinol, Fludarabine, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 156 | 2017-03-09 | 2023-09-21 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies Infusion of Treg - Acute Lymphoblastic Leukemia, Burkitt Lymphoma | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 3 | 2017-02-16 | 2020-09-29 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases Fludarabine, Cyclophosphamide, Total Body Irradiation - Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) | Not applicable | Terminated | Masonic Cancer Center, University of Minnesota | 200 | 2016-12-01 | 2026-05-20 |
| Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine Bendamustine, Cyclophosphamide - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 1 | Completed | University of Arizona | 50 | 2016-11-29 | 2025-11-10 |
| Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Ibrutinib - Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas | Phase 3 | Unknown | The University of Hong Kong | 62 | 2016-11-01 | 2018-04-12 |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule - Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Completed | Juno Therapeutics, a Subsidiary of Celgene | 387 | 2016-01-06 | 2024-06-27 |
| Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT subcutaneous Rituximab - Mantle-cell Lymphoma | Phase 2 | Unknown | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 36 | 2015-03-01 | 2020-01-27 |
| Safety Study of SGN-CD70A in Cancer Patients SGN-CD70A - Renal Cell Carcinoma, Mantle-Cell Lymphoma | Phase 1 | Completed | Seagen Inc. | 38 | 2014-08-01 | 2018-04-19 |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies Treg cells, CD3+ Teff cells, Fludarabine - Hematologic Malignancy, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2014-01-01 | 2017-12-02 |
Showing 20 of 30. Sign in to see all of them.
Lymphoma, Mantle-Cell (30) · Lymphoma, Follicular (15) · Leukemia, Lymphocytic, Chronic, B-Cell (14) · Lymphoma, B-Cell, Marginal Zone (12) · Lymphoma, Non-Hodgkin (11) · Leukemia, Myeloid, Acute (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Burkitt Lymphoma (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (8) · Lymphoma, Large B-Cell, Diffuse (7) · Multiple Myeloma (7) · Hodgkin Disease (5) · Leukemia, Prolymphocytic (5) · Myelodysplastic Syndromes (5) · Anemia, Refractory, with Excess of Blasts (4)
Hemic and Lymphatic Diseases (30) · Immune System Diseases (30) · Immunoproliferative Disorders (30) · Lymphatic Diseases (30) · Lymphoproliferative Disorders (30) · Neoplasms by Histologic Type (30) · Neoplasms (29) · Lymphoma (26) · Lymphoma, Non-Hodgkin (19) · Disease Attributes (16) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16) · Chronic Disease (15) · Hematologic Diseases (15) · Leukemia, Lymphoid (15)
Cyclophosphamide (10) · Rituximab (9) · fludarabine (6) · fludarabine phosphate (6) · Cyclosporine (4) · Mycophenolic Acid (4) · Whole-Body Irradiation (4) · Doxorubicin (3) · Etoposide (3) · Filgrastim (3) · Granulocyte Colony-Stimulating Factor (3) · Vincristine (3) · ibrutinib (3) · Antilymphocyte Serum (2) · Bendamustine Hydrochloride (2)
Masonic Cancer Center, University of Minnesota (7) · AstraZeneca (2) · Abramson Cancer Center at Penn Medicine (1) · Duke University (1) · Eli Lilly and Company (1) · Epizyme, Inc. (1) · Gemin X (1) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (1) · Heidelberg University (1) · Indiana University (1) · Juno Therapeutics, a Subsidiary of Celgene (1) · Massachusetts General Hospital (1) · Medical University of Vienna (1) · Novartis Pharmaceuticals (1) · Pharmacyclics LLC. (1)
United States (22) · Germany (4) · Spain (4) · Australia (3) · France (3) · Italy (3) · United Kingdom (3) · Czechia (2) · Netherlands (2) · South Korea (2) · Austria (1) · Belgium (1) · Canada (1) · China (1) · Denmark (1)
Claudio Brunstein, MD, PhD (2) · Andrea Aroldi (1) · Andres Lopez, DOCTOR (1) · Anne Beaven, MD (1) · Anthony D. Ho, Ph.D., Prof. (1) · Barbara Kiesewetter, MD (1) · Claudio Brunstein, MD (1) · David Miklos (1) · Elaina Gartner, MD (1) · Emmanuel Katsanis, MD (1) · Erica Warlick, MD (1) · Gary Acton, MD (1)
PMID 22563089, PMID 26009261, PMID 29908231, PMID 32582591, PMID 32888407, PMID 33720336, PMID 33735476, PMID 33904895, PMID 33970454, PMID 34125421, PMID 34310745, PMID 34398557, PMID 34493319, PMID 34515338, PMID 34717692, PMID 35156195, PMID 35337365, PMID 35460929, PMID 35610089, PMID 35847727, PMID 36755418, PMID 37467318, PMID 37890149, PMID 38072625, PMID 39914418, PMID 40270968, PMID 42209393, PMID 42237652, PMID 42462092
2016 (1), 2017 (1), P01CA049605 (1)